Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049413 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00049413 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian.
The verdict
NCT00049413, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining pentostatin and cyclophosphamide with rituximab in treating patients who have chronic lymphocytic leukemia or lymphocytic lymphoma.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG pentostatin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-06 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049413
The ClinicalTrials.gov registry entry for NCT00049413 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cyclophosphamide is the first listed.
NCT00049413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049413 about?
NCT00049413 is a clinical study titled "Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclona...
What is the current status of trial NCT00049413?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-06. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00049413?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), pentostatin (DRUG).
Who is sponsoring clinical trial NCT00049413?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.